ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases

LOS ANGELES: LOS ANGELES, Nov. 16, 2021 /PRNewswire/ -- ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, today announced the completion of a $250 million Series B financing led by AyurMaya, an affiliated fund of Matrix Capital Management ("Matrix"),...

Click to view original post